Skip to main content

Table 5 Risk of fracture associated with ADT by extent of disease and age

From: Risk of fracture in men with prostate cancer on androgen deprivation therapy: a population-based cohort study in New Zealand

  Adjusted OR (95 % CI) any fracture Adjusted OR (95 % CI) accidental fracture Adjusted OR (95 % CI) hip fracture
ADT a
 No 1.0 (Reference) 1.0 (Reference) 1.0 (Reference)
 Yes 2.83 (2.52–3.17) 1.47 (1.28–1.68) 1.82 (1.44–2.30)
Extent of disease a
 Localised
  No ADT 1.0 (Reference) 1.0 (Reference) 1.0 (Reference)
  ADT 3.42 (1.70–6.88) 1.85 (0.72–4.74) 6.56 (1.32–32.64)
Locally advanced or Metastatic
 No ADT 1.0 (Reference) 1.0 (Reference) 1.0 (Reference)
 ADT 3.73 (2.83–4.91) 1.38 (0.94–2.05) 3.43 (1.44–8.19)
Unknown
 No ADT 1.0 (Reference) 1.0 (Reference) 1.0 (Reference)
 ADT 2.21 (1.93–2.52) 1.40 (1.20–1.63) 1.60 (1.25–2.06)
Age b
 < 65
  No ADT 1.0 (Reference) 1.0 (Reference) 1.0 (Reference)
  ADT 4.67 (3.76–5.81) 1.50 (1.10–2.05) 2.02 (0.93–4.39)
 ≥ 65
  No ADT 1.0 (Reference) 1.0 (Reference) 1.0 (Reference)
  ADT 2.89 (2.55–3.29) 1.87 (1.61–2.17) 2.53 (1.99–3.22)
  1. ADT androgen deprivation therapy, OR odds ratio, CI confidence interval
  2. aAdjusted for age of diagnosis and ethnicity
  3. bAdjusted for ethnicity
  4. Bold indicate significant p-value (<0.5)